Cormedix Analyst Price Targets

Cormedix Inc

CRMDNASDAQ

Trade with Public

$7.26

-0.20-2.68%

마지막 업데이트: Oct 16, 6:33 PM

$7.26

-0.20-2.68%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 주식 보고서

Cormedix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cormedix (CRMD).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

2S.Buy

8Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$16Upside to Avg. PT+114.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$15
Aug 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$14→$13
Apr 28, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
Apr 28, 2026	Citizens	Jason N. Butler	Maintained	Market Outperform	$19
Apr 28, 2026	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$13→$14
Apr 27, 2026	Needham	Serge Belanger	PT Raise	Buy	$14→$15
Apr 27, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Mar 5, 2026	Needham	Serge Belanger	PT Cut	Buy	$15→$14
Feb 11, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Jan 23, 2026	HC Wainwright & Co.	Brandon Folkes	PT Cut	Buy	$18→$13
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$22→$13
Jan 8, 2026	Needham	Serge Belanger	PT Cut	Buy	$16→$15
Jan 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Dec 18, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Nov 13, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$17→$18
Nov 12, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Nov 12, 2025	Needham	Serge Belanger	PT Cut	Buy	$20→$16
Oct 21, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$21→$22
Oct 20, 2025	D. Boral Capital	Jason Kolbert	Upgrade	Hold→Buy	$14

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $14 to $13.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

Citizens analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $19 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

Leerink Partners analyst Roanna Ruiz maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

Cormedix Inc

Cormedix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

뉴스

파트너 / 기고자

벤징가 글로벌

Cormedix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

People Also Watch

People Also Watch

Cormedix Inc

Cormedix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRORBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PROCitizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PROLeerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

뉴스

파트너 / 기고자

벤징가 글로벌

Cormedix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRORBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PROCitizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PROLeerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14